Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $32.00. The company’s shares closed today at $26.41. Discover ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares closed yesterday at $26.01. According to ...

However, at least two conditions listed as adverse events also appeared in Pfizer's 2024 list of genuine side effects. In January 2025, Snopes readers asked us about the authenticity of a long ...

NEW YORK (Reuters) - Pfizer on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider trading settlement involving billionaire Steven A.

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the cash-strapped biotech of up to $220 million in milestones. Pfizer’s decision sent ...

NEW YORK, Jan 14 (Reuters) - Pfizer (PFE.N), opens new tab on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider trading settlement ...

Pfizer targets $4 billion in operational savings ... Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate ...

Stanley Goldfarb, Do No Harm's chair, in a statement said it was pleased the court "reversed course and correctly recognized our right to protect our members in the district court." Pfizer in a ...

Stanley Goldfarb, Do No Harm's chair, in a statement said it was pleased the court "reversed course and correctly recognized our right to protect our members in the district court." Pfizer in a ...

Dec 30 (Reuters) - Sangamo Therapeutics (SGMO.O), opens new tab said on Monday that partner Pfizer (PFE.N), opens new tab has terminated their hemophilia A gene therapy co-development agreement ...

Pfizer has abandoned development of a hemophilia A gene therapy it licensed from Sangamo Therapeutics, a move that could imperil Sangamo’s future. It’s a sudden turnabout for Pfizer, which had ...

Here are three reasons to consider buying Pfizer like there's no tomorrow -- today. As terrible as COVID-19 was for society, it was undeniably a windfall for Pfizer. The company's two COVID-19 ...